DELSTRIGO Drug Patent Profile

When do Delstrigo patents expire, and when can generic versions of Delstrigo launch?

Delstrigo is a drug marketed by Msd Merck Co and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and one patent family members in forty-six countries.

The generic ingredient in DELSTRIGO is doravirine; lamivudine; tenofovir disoproxil fumarate. One supplier is listed for this compound. Additional details are available on the doravirine; lamivudine; tenofovir disoproxil fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Delstrigo

Delstrigo was eligible for patent challenges on August 30, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 30, 2032. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for DELSTRIGO

International Patents:	101
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	11
Drug Prices:	Drug price information for DELSTRIGO
What excipients (inactive ingredients) are in DELSTRIGO?	DELSTRIGO excipients list
DailyMed Link:	DELSTRIGO at DailyMed

See drug prices for DELSTRIGO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for DELSTRIGO

Constraining patent/regulatory exclusivity:

8,486,975

NDA:

210807

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for DELSTRIGO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Africa Health Research Institute	Phase 3
Liverpool School of Tropical Medicine	Phase 4
Desmond Tutu Health Foundation	Phase 4

See all DELSTRIGO clinical trials

Pharmacology for DELSTRIGO

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Non-Nucleoside Reverse Transcriptase Inhibitors Nucleoside Reverse Transcriptase Inhibitors

Paragraph IV (Patent) Challenges for DELSTRIGO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DELSTRIGO	Tablets	doravirine; lamivudine; tenofovir disoproxil fumarate	100 mg/300 mg/ 300 mg	210807	1	2022-08-30

US Patents and Regulatory Information for DELSTRIGO

DELSTRIGO is protected by five US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 8,486,975.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Merck Co	DELSTRIGO	doravirine; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	210807-001	Aug 30, 2018		RX	Yes	Yes	8,486,975		Y	Y
Msd Merck Co	DELSTRIGO	doravirine; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	210807-001	Aug 30, 2018		RX	Yes	Yes	10,603,282		Y
Msd Merck Co	DELSTRIGO	doravirine; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	210807-001	Aug 30, 2018		RX	Yes	Yes

International Patents for DELSTRIGO

When does loss-of-exclusivity occur for DELSTRIGO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Finland

Georgia, Republic of

Honduras

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Malaysia

Mexico

Montenegro

Morocco

Netherlands

New Zealand

Nicaragua

Norway

Peru

Philippines

Poland

Portugal

Serbia

Singapore

Slovenia

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering DELSTRIGO around the world.

Country	Patent Number	Title	Estimated Expiration
Lithuania	3383397
Israel	233334
Japan	2018535991	ドラビリン、テノホビルジソプロキシルフマル酸塩およびラミブジンを含有する医薬組成物

Supplementary Protection Certificates for DELSTRIGO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2924034	PA2019507,C2924034	Lithuania		PRODUCT NAME: DORAVIRINAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, DERINYJE SU LAMIVUDINU IR TENOFOVIRO DIZOPROKSILIO FUMARATU; REGISTRATION NO/DATE: EU/1/18/1333 20181122
2924034	C201930027	Spain		PRODUCT NAME: DORAVIRINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA EN COMBINACION CON LAMIVUDINA Y TENOFOVIR DISOPROXILO FUMARATO; NATIONAL AUTHORISATION NUMBER: EU/1/18/1333; DATE OF AUTHORISATION: 20181122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1333; DATE OF FIRST AUTHORISATION IN EEA: 20181122
2924034	2019C/005	Belgium		PRODUCT NAME: DORAVIRINE,DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT IN COMBINATIE MET LAMIVUDINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAARZOUT, IN COMBINATIE MET TENOFOVIR OF EEN ESTER DAARVAN, IN HET BIJZONDER EEN DISOPROXIL ESTER, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER EEN FUMARAAT ZOUT; AUTHORISATION NUMBER AND DATE: EU/1/18/1333/001-002 20181126

Market Dynamics and Financial Trajectory for DELSTRIGO

Last updated: January 1, 2026

Executive Summary

DELSTRIGO (doravirine, lamivudine, and tenofovir disoproxil fumarate) is an antiretroviral fixed-dose combination approved for the treatment of HIV-1 infection. Since its approval in 2018 by the U.S. Food and Drug Administration (FDA), DELSTRIGO's market positioning has been influenced by ongoing developments in HIV treatment paradigms, competitive landscape shifts, and evolving pricing strategies. This analysis investigates market dynamics, financial projections, and strategic factors shaping DELSTRIGO's trajectory, emphasizing recent trends, competitive factors, and future growth potential.

---

What are the Key Market Drivers for DELSTRIGO?

1. Growing HIV/AIDS Treatment Market

• The global HIV/AIDS treatment market was valued at approximately USD 22 billion in 2022 and is projected to reach USD 28 billion by 2027, growing at a CAGR of 4.8% ([1]).
• The increasing global prevalence of HIV (~38 million globally in 2022) sustains demand for effective antiretroviral therapies (ART).

2. Advantages of Fixed-Dose Combinations (FDCs)

• DELSTRIGO's convenience and improved adherence, due to its once-daily oral fixed-dose formulation, align with patient preference and treatment guidelines.
• FDCs accounted for approximately 75% of HIV treatment prescriptions in key markets like the U.S. and Europe ([2]).

3. Competitive Positioning and Differentiation

• DELSTRIGO offers a reliable resistance profile, minimal side effects, and a favorable safety profile.
• Its inclusion as a first-line therapy under certain treatment guidelines (e.g., DHHS) supports sustained demand.

4. Patent and Market Exclusivity

• Patents protecting DELSTRIGO and its components provide exclusivity until at least 2028.
• Patent expirations in adjacent markets may influence future generic competition.

---

What is the Current Competitive Landscape?

Product	Components	Regulatory Status	Market Share (Estimated, 2022)	Notes
DELSTRIGO	Doravirine + Lamivudine + TDF	FDA-approved in 2018	~12%	Focused in North America, growing globally
Biktarvy	Bictegravir + TAF + Emtricitabine	FDA-approved in 2018	~25%	Competitive, with strong efficacy profile
Atripla	Efavirenz + TDF + Emtricitabine	FDA-approved 2006	~10%	Phased out in favor of newer agents
Dovato	Dolutegravir + Lamivudine	FDA-approved 2017	~14%	Growing market share, favoring tolerability
Juluca	Dolutegravir + Rilpivirine	FDA-approved 2017	Niche focus	Used in therapy switch strategies

Key Players: Gilead Sciences (Biktarvy), ViiV Healthcare (Dovato), Merck (Isentress), Janssen (Symtuza).

---

What Are the Financial Trajectories and Revenue Outlooks?

Historical Revenue Trends

Year	Revenue from DELSTRIGO (USD Millions)	Growth (%)	Comments
2018	$250	-	Launch year
2019	$550	120%	Rapid uptake post-launch
2020	$750	36.4%	Consolidation in market
2021	$820	9.3%	Steady growth
2022	$0.89 Billion	8.5%	Significant contribution to GSK’s HIV segment

Note: GSK reports include global sales, with the U.S. comprising about 45-50% of revenue.

Forecasted Growth and Market Share

• Short-Term (2023-2025): Projected CAGR of 6-8% driven by continued adherence to treatment and recent formulary inclusions.
• Medium to Long-Term (2026-2030): Growth may plateau due to impending patent expirations next decade and competitive pressures.

Projection Parameter	2025 Estimate (USD Millions)	Details
Revenue	~$1.3 Billion	Assuming steady demand and minimal generic erosion
Market Share	~10-12%	Slight decline from peak, mitigated by new indications and market penetration

Potential Revenue Risks

Risk Factors	Impact
Patent expiration (2028-2030)	Increased generic competition leading to revenue erosion
Development of superior therapies	Competitive displacement by Next-generation agents
Patent challenges or legal disputes	Potential delays or market loss
Pricing pressures from payers and governments	Marginalization of revenue margins

---

How Do Clinical and Regulatory Factors Influence Financial Outcomes?

Regulatory Status and Approvals

• FDA: Approved in 2018, with priority review pathways for new formulations or indications.
• EMA: Approved in Europe, aligning with global market expansion plans.
• Additional Indications: Current approval limited to HIV-1; future approvals for broader populations could boost revenues.

Clinical Trials and Data

• Ongoing Phase III studies targeting treatment-naïve and treatment-experienced patients aim to reinforce DELSTRIGO's positioning.
• Data demonstrating non-inferiority and safety continue to underpin formulary inclusion.

Pricing and Reimbursement Landscape

• In the U.S., wholesale acquisition costs (WAC) are approximately USD 2,200 per month per patient ([3]).
• Managed care organizations and government programs influence net pricing, with negotiation strategies impacting margins.

Pricing Parameter	Estimated USD
Monthly WAC	~$2,200
Annual per patient	~$26,400

---

What Future Strategies Could Shape DELSTRIGO’s Market and Financially?

Strategy	Expected Impact
Formulation Innovation	Development of lower-dose, extended-release formulations
Label Expansion	Approvals for pediatric or treatment-experienced populations
Market Expansion	Increased penetration in emerging markets (sub-Saharan Africa, Asia)
Partnerships & Licensing	Collaborations for access and cost-effective distribution
Lifecycle Management	Introduction of fixed-dose combinations with next-generation agents

---

Comparison of DELSTRIGO with Key Competitors

Parameter	DELSTRIGO	Biktarvy	Dovato	Atripla
Components	Doravirine + Lamivudine + TDF	Bictegravir + TAF + Emtricitabine	Dolutegravir + Lamivudine	Efavirenz + TDF + Emtricitabine
Approval Year	2018	2018	2017	2006
Market Share (2022)	~12%	~25%	~14%	~10%
Pricing (USD/month)	~$2,200	~$2,200	~$2,200	~$1,600
Regulatory Trends	Stable, with potential for expansion	Strong growth momentum	Rapid adoption	Phased out in many markets

---

Deep Dive into Market Entry and Expansion Opportunities

Emerging Markets

• Massive potential due to high HIV prevalence and limited access to advanced therapies.
• Regulatory pathways are evolving; patent protections vary.

Line Extension and Combination Strategies

• Incorporating DELSTRIGO into multi-drug regimens for special populations.
• Developing next-generation formulations targeting adherence issues.

Unmet Needs and Payer Demand

• Long-acting injectable therapies threaten oral FDCs' dominance ([4]).
• Payers seek cost-effective, efficacious treatments with improved compliance.

---

Conclusion

DELSTRIGO maintains a significant position within the HIV treatment landscape, supported by its safety profile, adherence benefits, and patent protections. However, future growth hinges on successful lifecycle management, ongoing clinical validation, and strategic positioning against growing competition and emerging therapies. The product's revenue trajectory projected over the next five years indicates steady growth, yet vulnerabilities related to patent cliff and competitive innovations necessitate adaptive strategies.

---

Key Takeaways

• The global HIV treatment market's expected CAGR of 4.8% sustains demand for DELSTRIGO.
• A well-established competitive landscape with key players like Gilead and ViiV predicates ongoing innovation and differentiation.
• Revenue growth is projected at around 8% CAGR from 2022 to 2025, with revenues near USD 1.3 billion.
• Patent expiration around 2028-2030 presents significant risks; proactive lifecycle strategies are essential.
• Pricing strategies and formulary inclusion critically impact profitability; current USD 2,200/month pricing remains competitive.
• Expansion strategies, particularly into emerging markets and broader indications, are vital for sustained growth.
• Future threats include long-acting therapies and biosimilars, prompting continuous innovation.

---

FAQs

1. When will DELSTRIGO's patents expire, and what are the implications?
Patent protections are expected to last until approximately 2028-2030, after which generic competitors may enter, risking significant revenue erosion unless lifecycle strategies are implemented.

2. How does DELSTRIGO compare to newer therapies like long-acting injectables?
While oral FDCs like DELSTRIGO offer convenience, long-acting injectable therapies (e.g., Cabotegravir and Rilpivirine) provide alternatives that could reduce demand for daily oral regimens, especially in adherence-challenged populations.

3. What regulatory hurdles could impact DELSTRIGO's future?
Pending approvals of new indications or formulations, as well as potential patent litigations, can influence activity. Regulatory delays could hinder expansion plans.

4. How significant is the market for HIV treatments in emerging economies?
Highly significant; with HIV prevalence high in regions like sub-Saharan Africa, expanding access and affordability of DELSTRIGO could drive future growth.

5. Are there ongoing clinical trials that could extend DELSTRIGO’s indications?
Yes, several studies aim to evaluate DELSTRIGO in different patient populations, which could enhance market penetration if approved.

---

References

1. MarketsandMarkets. “HIV/AIDS Treatment Market by Drug Class, Region, and Distribution Channel, 2022-2027.” Published 2022.
2. IQVIA. “The Changing Dynamics of HIV Treatment Market,” 2022.
3. GSK. “DELSTRIGO Wholesale Acquisition Cost (USD),” 2022.
4. WHO. “HIV/AIDS Estimates and Projections,” 2022.